Ganesh Benzoplast Q1 Results: Revenue Jumps 23% but EBITDA Margin Narrows Sharply
Ganesh Benzoplast reported Q1FY27 consolidated revenue of ₹1,174.95 million (+23% YoY) and net profit of ₹175.82 million (-3% YoY). EBITDA declined to ₹270 million from ₹291 million, with EBITDA margin narrowing sharply to 22.98% from 30.44%, driven by a 34% surge in other expenses. The Chemical Division led growth with a 27% revenue increase, while the LST Division saw segment profits decline.

*this image is generated using AI for illustrative purposes only.
Ganesh Benzoplast Limited reported a consolidated net profit of ₹175.82 million for the quarter ended June 30, 2026 (Q1FY27), a 3% decline from ₹181.33 million in the corresponding period of FY26. Consolidated revenue from operations surged 23% year-on-year to ₹1,174.95 million, up from ₹956.18 million in Q1FY26. However, EBITDA declined to ₹270 million from ₹291 million in the same period last year, with the EBITDA margin contracting sharply to 22.98% from 30.44% year-on-year, highlighting significant margin pressure despite robust top-line growth. The results were approved by the Board of Directors on August 11, 2026, and reviewed by statutory auditors Mittal & Associates under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Standalone net profit fell 5% to ₹134.40 million from ₹140.91 million in Q1FY26, while standalone revenue rose 24% to ₹703.39 million. Earnings per share (basic) stood at ₹2.44 for consolidated results and ₹1.87 for standalone results, compared to ₹2.52 and ₹2.06 respectively in the prior year quarter.
Key Financial Highlights
The following table summarises the key consolidated and standalone financial metrics for the quarter:
| Metric: | Q1FY27 | Q1FY26 | Change |
|---|---|---|---|
| Consolidated Revenue (₹ Million): | 1,174.95 | 956.18 | +23% |
| Consolidated Net Profit (₹ Million): | 175.82 | 181.33 | -3% |
| EBITDA (₹ Million): | 270 | 291 | Decline |
| EBITDA Margin (%): | 22.98 | 30.44 | Contraction |
| Standalone Revenue (₹ Million): | 703.39 | — | +24% YoY |
| Standalone Net Profit (₹ Million): | 134.40 | 140.91 | -5% |
| EPS – Consolidated (₹): | 2.44 | 2.52 | — |
| EPS – Standalone (₹): | 1.87 | 2.06 | — |
Segment Performance
The Chemical Division emerged as the primary growth engine in Q1FY27. Revenue from this segment increased by 27% year-on-year to ₹626.93 million, contributing significantly to the overall top-line expansion. The segment's profit before tax and interest but after depreciation rose sharply to ₹81.53 million from ₹71.95 million in Q1FY26. In contrast, the Logistics, Supply Chain & Infrastructure (LST) Division saw revenue grow more modestly by 18% to ₹548.03 million, with segment profits declining to ₹179.03 million from ₹210.66 million in the same period last year.
| Segment: | Revenue (₹ Million) | YoY Change | Segment Profit (₹ Million) |
|---|---|---|---|
| Chemical Division: | 626.93 | +27% | 81.53 |
| LST Division: | 548.03 | +18% | 179.03 |
| Total: | 1,174.96 | +23% | 260.56 |
Note: LST Division includes EPC, Wharfage Income & Rail Logistic.
Margin Pressure and Cost Dynamics
The EBITDA margin compression from 30.44% to 22.98% underscores a key divergence in Q1FY27 results — the decoupling of revenue growth from profitability at the consolidated level. While revenue expanded by 23%, the sharp decline in EBITDA margin points to rising operational costs outpacing top-line gains. Specifically, 'Other expenses' in the consolidated statement rose to ₹464.24 million from ₹345.52 million in Q1FY26, a 34% increase that outpaced revenue growth. The standalone results show a similar pattern, with other expenses jumping to ₹329.31 million from ₹250.73 million, indicating sustained pressure on operating margins despite top-line gains. Finance costs in the consolidated statement stood at ₹20.07 million compared to ₹23.28 million in the prior year, reflecting a slight decrease.
Legal Developments
The auditor's report included an emphasis of matter regarding a First Information Report (FIR) and complaint registered with the Economic Office Wing (EOW) against the parent company, its directors, and key managerial personnel in July 2024. The allegations relate to loans and borrowings allegedly undertaken in FY23-24 by the then director of GBL Chemical Ltd and the CEO through an unauthorized bank account with State Bank of India. Ganesh Benzoplast Limited has filed a petition to quash the FIR, which is currently pending before the High Court of Delhi. The company stated that it had reported the event to exchanges and authorities immediately upon occurrence.
Historical Stock Returns for Ganesh Benzoplast
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -3.01% | +2.73% | +20.41% | +44.80% | +27.52% | +23.60% |
What specific operational or input cost drivers contributed to the 34% surge in 'Other expenses', and are these costs expected to normalize in subsequent quarters?
How might the pending legal proceedings regarding the unauthorized bank account allegations impact Ganesh Benzoplast's credit ratings or ability to secure future financing?
Given the sharp EBITDA margin contraction despite robust revenue growth, what strategic measures is management implementing to restore profitability to previous levels?


































